Non-TBI Hematopoietic Stem Cell Transplantation in Pediatric AML Patients

Hamidieh, Amir Ali; Jahani, M.; Bahar, Burhanuddin; Mousavi, Seyed Asadollah; Iravani, M.R.; Behfar, Maryam; Jalali, Arash; Jalili, Mahdi; Hamdi, Amir; Ghavamzadeh, Ardeshir

doi:10.1097/mph.0b013e31827080fc

Cited by 6 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,[38][39][40][41] Furthermore, OS and DFS in the nonmalignant subset including Thalassemia and severe aplastic anemia cases were comparable with other studies of allogeneic transplantation from sibling donors. 40,[42][43][44][45][46] The overall rates of aGvHD and cGvHD in both malignant and non-malignant subsets were comparable with other studies applying sibling donors. [47][48][49][50] As one might predict, PBSC was accompanied with higher risk of cGvHD and aGvHD.…”

Section: Discussionsupporting

confidence: 70%

Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: A new prospect of exploiting extended family search

Hamidieh

Dehaghi

Paragomi

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

The best donors for hematopoietic SCT (HSCT) are fully-matched siblings. In patients without fully-matched siblings, HLA registries or cord blood banks are alternative strategies with some restrictions. Owing to the high rate of consanguineous marriage in our country, between 2006 and 2013, extended family searches were undertaken in Hematology-Oncology Research Center and Stem Cell Transplantation (HORCSCT), Tehran, Iran, in 523 HSCT candidates with parental consanguinity and no available HLA identical sibling. Fully-matched other-relative donors were found for 109 cases. We retrospectively studied the HSCT outcome in these patients. Median time to neutrophil engraftment was 13 days (range: 9-31days). In 83 patients, full chimerism and in 17 patients, mixed chimerism was achieved. Acute GvHD (aGvHD) grade II-IV appeared in 36 patients (33%). The frequency of aGvHD development in various familial subgroups was NS. Five patients expired before day+100. In the surviving 104 cases, chronic GvHD developed in 20 patients (19.2%). The distantly related subgroup had significantly a higher rate of cGvHD (P = 0.04). The 2-year OS and disease-free survival (DFS) were 76.7 ± 4.5% and 71.7 ± 4.7%, respectively. No significant difference in OS (P = 0.30) and DFS (P = 0.80) was unraveled between various familial relationships. Our considerable rate of fully-matched non-sibling family members and the favorable outcome support the rationale for extended family search in regions where consanguineous marriage is widely practiced.

show abstract

Section: Discussionsupporting

confidence: 70%

Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: A new prospect of exploiting extended family search

Hamidieh

Dehaghi

Paragomi

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Finally, female sex has previously been noted to be a risk factor for adverse outcome in patients transplanted at our institution before 2004 (Orchard et al 2010), and our current study extends this finding to the era of 2004 onward. Although unusual, at least one study finds a female survival disadvantage after HSCT for acute myelogenous leukemia (Hamidieh et al 2013), and another suggests females may be more susceptible to busulfan toxicity (Ansari et al 2014). It is also possible that there are disease-related factors in females with MPS IH that are as yet not recognized and contribute to this observance.…”

Section: Discussionmentioning

confidence: 99%

Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30‐year University of Minnesota experience

Rodgers

Kaizer

Miller

et al. 2017

J of Inher Metab Disea

View full text Add to dashboard Cite

show abstract

“…Despite of the major advances in histocompatibility testing techniques, more aggressive matching programs, and the developement of more efficient immunosuppressive drugs, this therapeutic procedure is still burdened with a relatively high mortality rate, which ranges between 10 and 30% [1][2][3][4]. As an increasing number of transplants are being performed in OPEN    ACCESS older patients, and many of them are long term survivors, the incidence of the chronic graft versus host disease (GVHD) rises in the recent years and it reaches rates above 50% [5,6].…”

Section: Introductionmentioning

confidence: 99%

Association of Killer Cell Immunoglobulin-Like Receptor Genes with the Graft versus Host Disease after Related Haematopoietic Stem Cell Transplantation in Patients with Haematological Malignancies from Republic of Macedonia

et al. 2012

View full text Add to dashboard Cite

Aim: The aim of this study was to examine the gene frequencies of 16 KIR genes and pseudogenes and KIR genotypes in Macedonian patients with transplanted bone marrow and their sibling donors in treatment of haematological malignancy, and to analyse eventual association of the gene content with the occurrence of a graft versus host disease (GVHD). Material and Methods:The study was performed on 24 patients and their HLA-matched sibling donors. Results:Comparison of KIR gene frequencies between the total 24 donors and healthy Macedonians reveals statistically significant difference for KIR2DS1 (F= 0.481 in the controls group, and 0.76 in the patients group, p=0.004). This significance is even higher when the frequency of KIR2DS1 in controls is compared with the frequency in donors from pairs with GVHD (F= 0.923, P= 0.002). Another significant difference was observed for the frequency of the full-length allele of KIR2DS4*001-002, present in 25.2% of the control individuals, but in as much as 81.8% of the recipients of haematopoietic stem cell (P=0.0005). We did not see any statistically significant difference in distribution of the C1/C1, C1/C2 and C2/C2 groups among GVHD pairs. Conclusion:Our results address the difference between the haematopoietic stem cell transplantation settings with sibling and unrelated donors and suggest that the KIR2DS4*001/002 might be a predisposing factor for severe GVHD in sibling HSCT.

show abstract

Non-TBI Hematopoietic Stem Cell Transplantation in Pediatric AML Patients

Abstract: The role of allo-HSCT in pediatric AML patients in first complete remission is uncertain. Further randomized studies are recommended to clarify the optimal postremission therapy in these patients.

Cited by 6 publications

References 40 publications

Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: A new prospect of exploiting extended family search

Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: A new prospect of exploiting extended family search

Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30‐year University of Minnesota experience

Association of Killer Cell Immunoglobulin-Like Receptor Genes with the Graft versus Host Disease after Related Haematopoietic Stem Cell Transplantation in Patients with Haematological Malignancies from Republic of Macedonia

Contact Info

Product

Resources

About